WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Employees

12,435

Sector

Biotechnology & Medical Research

Calendar

22/09/2024 - BioProcess International conference

More about the company

Quotes

Date	Price	Change	Volume
19/09/24	12.12 $	+5.21%	75,417,794
17/09/24	11.52 $	+0.52%	13,727,640
16/09/24	11.46 $	-0.69%	14,252,250
13/09/24	11.54 $	-1.20%	42,977,080
12/09/24	11.68 $	+3.36%	80,788,990

Delayed Quote Hong Kong S.E., September 19, 2024 at 09:08 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.49CNY

Average target price

17.55CNY

Spread / Average Target

+67.36%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 09:08:11 19/09/2024 BST			5-day change	1st Jan Change
12.12 ^HKD	+5.21%		+3.77%	-59.05%

09-12	US Biosecure Act Could Boost South Korean Biotech Companies, Report Says	MT
09-11	China Condemns US House's Passing of Bill Targeting Biotech Companies	MT

Capitalization	43.15B 6.1B 47.56B 461B	P/E ratio 2024 *	12.8x	P/E ratio 2025 *	10.9x
Enterprise value	108B 15.28B 119B 1,153B	EV / Sales 2024 *	1.99x	EV / Sales 2025 *	1.72x
Free-Float	85.36%	Yield 2024 *	-	Yield 2025 *	-

US Biosecure Act Could Boost South Korean Biotech Companies, Report Says	09-12	MT
China Condemns US House's Passing of Bill Targeting Biotech Companies	09-11	MT
European stocks mixed before eyes turn stateside	09-10	AN
WuXi Biologics (Cayman) Issues Response After US House OKs Biosecure Bill; Stocks Slide 4%	09-10	MT
WuXi Companies Say They're Not a Security Risk as U.S. Passes Draft of Biosecure Act -- Update	09-10	DJ
WuXi Companies Reaffirm No Security Risk as U.S. House Passes Draft Biosecure Act	09-10	DJ
US Democrat Congressman to Block Bill Banning Business with Chinese Biotech Firms	09-09	MT
Democrat to vote against bill restricting China's WuXi Biologics, BGI	09-07	RE
WuXi Biologics Inc. commences an Equity Buyback Plan for 415,129,694 shares, representing 10% of its issued share capital, under the authorization approved on June 19, 2024.	09-02	CI
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing	08-30	CI
WuXi Biologics Inc. entered into the Equity Transfer Agreement to acquire remaining 30% stake in WuXi Vaccines Inc. from Shanghai Hile Bio-Technology Co., Ltd. for approximately $110 million.	08-29	CI
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$19.30 From HK$23.25, Keeps at Buy	08-22	MT
WuXi Biologics' H1 Profit Falls 34% as Revenue Marginally Rises; Shares Down 4%	08-22	MT

Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$19.30 From HK$23.25, Keeps at Buy	08-22	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$23.25 From HK$53.65, Keeps at Buy	07-24	MT
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	06-27	MT
Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3%	05-17	MT
Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy	03-01	MT

WuXi Biologics (Cayman) Inc. Share Price

Equities

2269

KYG970081173

Biotechnology & Medical Research

Valuation: WuXi Biologics (Cayman) Inc.

Chart: WuXi Biologics (Cayman) Inc.

Latest news: WuXi Biologics (Cayman) Inc.

Last Transcript: WuXi Biologics (Cayman) Inc.

Analysts' recommendations: WuXi Biologics (Cayman) Inc.

Press Releases: WuXi Biologics (Cayman) Inc.

News in other languages: WuXi Biologics (Cayman) Inc.

Quotes and Performance

Course Extremes

Managers and Directors: WuXi Biologics (Cayman) Inc.

ETFs: WuXi Biologics (Cayman) Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUITM in 2,000L GMP Manufacturing	09-02	AQ
WuXi Biologics Cayman : 2024 Interim Results	08-21	PU
WuXi Biologics Cayman : Reports Solid 2024 Interim Results	08-21	PU
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers	08-09	AQ
WuXi Biologics Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics	08-02	AQ

MÄRKTE ASIEN/Uneinheitlich - Anleger halten sich vor US-Daten zurück	09-10
MÄRKTE ASIEN/Etwas fester - US-Biotech-Gesetz belastet in China	09-10
MÄRKTE ASIEN/Yen auf 34-Jahres-Tief stützt Kurse in Tokio	03-27
MÄRKTE ASIEN/Uneinheitlich - Schwacher Yen stützt Kurse in Tokio	03-27
MÄRKTE ASIEN/Leichter - Gewinnmitnahmen drücken Nikkei-Index um 1,2%	03-25

1 day	+5.21%
1 week	+3.77%
Current month	+8.02%
1 month	+1.68%
3 months	+1.51%
6 months	-12.93%
Current year	-59.05%

Director	Title	Age	Since
Zhi Sheng Chen CEO	Chief Executive Officer	52	31/05/11
Ming Tu DFI	Director of Finance/CFO	54	22/08/21
Ji Jie Gu CTO	Chief Tech/Sci/R&D Officer	57	-

Manager	Title	Age	Since
Ge Li CHM	Chairman	56	30/04/10
Zhi Sheng Chen CEO	Chief Executive Officer	52	31/05/11
Wei Chang Zhou BRD	Director/Board Member	59	30/11/12

Name	Weight	AuM	1st Jan change	Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	9.62%	1 M€	-20.08%	-
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD	4.23%	2 M€	-2.90%	-
GLOBAL X CHINA DISRUPTION ETF - USD	3.58%	1 M€	-9.86%	-
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	2.95%	2 M€	-.--%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
WUXI BIOLOGICS (CAYMAN) INC.	+5.21%	+3.77%	-72.07%	-90.01%	6.08B
VERTEX PHARMACEUTICALS INCORPORATED	-1.48%	-0.12%	+34.70%	+151.81%	124B
REGENERON PHARMACEUTICALS, INC.	-0.69%	-0.23%	+38.12%	+74.70%	124B
ARGENX SE	-0.15%	-2.24%	-2.80%	+71.83%	31.62B
BIONTECH SE	-7.29%	+16.47%	+6.03%	-67.81%	29.65B
BEIGENE, LTD.	-0.12%	-6.57%	-5.57%	-51.06%	21B
SUMMIT THERAPEUTICS INC.	-6.33%	+8.19%	+1,256.91%	+284.95%	19.27B
GENMAB A/S	+0.80%	-0.59%	-31.72%	-35.46%	16.66B
WUXI APPTEC CO., LTD.	+0.50%	+3.84%	-50.59%	-73.74%	16.12B
VAXCYTE, INC.	-0.18%	+2.63%	+129.45%	+359.54%	14.44B
Average	-0.97%	+2.74%	+130.25%	+62.48%	40.28B
Weighted average by Cap.	-1.40%	+1.26%	+82.68%	+88.49%

	2024 *	2025 *
Net sales	17.88B 2.53B 19.71B 191B	20.18B 2.85B 22.24B 216B
Net income	3.35B 473M 3.69B 35.72B	4.05B 573M 4.46B 43.24B
Net Debt	-7.5B -1.06B -8.26B -80.05B	-8.39B -1.19B -9.25B -89.62B